Andrew Hirsch Named Chief Executive Officer of C4 Therapeutics

WATERTOWN, Mass, September 8, 2020 – C4 Therapeutics, Inc. (C4T), a biopharmaceutical company pioneering a new class of small-molecule drugs that selectively destroy disease-causing proteins through degradation, today announced the hiring of Andrew Hirsch as the Company’s incoming chief executive officer. Mr. Hirsch comes to C4T from Agios Pharmaceuticals where he was chief financial officer…

C4 Therapeutics Announces the Additions of William McKee as Chief Financial Officer and Jolie M. Siegel as Chief Legal Officer

WATERTOWN, Mass, July 15, 2020 – C4 Therapeutics, Inc. (C4T), a biotechnology company pioneering a new class of small-molecule drugs that selectively destroy disease-causing proteins via degradation, today announced the addition of William McKee and Jolie M. Siegel to its leadership team as Chief Financial Officer and Chief Legal Officer, respectively. Mr. McKee currently also…

C4 Therapeutics Raises $170 Million Financing to Bring Robust Pipeline of Protein Degraders to Clinical Proof-of-concept and to Advance Proprietary Platform

–Multiple oncology-focused programs poised to enter clinical trials in 2021 and 2022– WATERTOWN, Mass, June 16, 2020 – C4 Therapeutics, Inc. (C4T), a biotechnology company pioneering a new class of small-molecule drugs that selectively destroy disease-causing proteins via degradation, today announced the closing of a $170 million financing, including $150 million in Series B equity co-led by existing…